The europe in vitro diagnostics market size was estimated at USD 16.36 billion in 2022 and is expected to hit around USD 26.14 billion by 2032, poised to reach at a notable CAGR of 4.8% during the forecast period 2023 to 2032.
Covid-19 Impact On Europe In Vitro Diagnostics Market
Europe observed social distancing through nationwide lockdowns during the COVID-19 pandemic. This lead diverse changes in every industry such as new challenges in supply chains, rising and falling demands of products, availability of resources and others. Similarly, in vitro diagnostics market in Europe was also affected by the COVID-19 outbreak. In addition, the impact was either positive or negative for different sectors of in vitro diagnostics industry. For instance, the impact of nationwide lockdowns in Europe was not favorable for the some of the in vitro diagnostic services. However, the sudden demand for new IVD products for COVID-19 testing resulted in key players launching various type of test kits. Therefore, the new test kits were granted Conformité Européene (CE) Mark in Europe which ensured the availability of safe the test kits.
Europe In Vitro Diagnostics Market Report Scope
Report Attribute | Details |
Market Size in 2023 | USD 17.14 Billion |
Market Size by 2032 | USD 26.14 Billion |
Growth Rate From 2023 to 2032 | CAGR of 4.8% |
Base Year | 2022 |
Forecast Period | 2023 to 2032 |
Segments Covered | Product Services, Techniques, Application, End User, Country |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Key Companies Profiled | THERMO FISHER SCIENTIFIC, INC., BECTON, DICKINSON AND COMPANY, HOFFMANN-LA ROCHE AG., SIEMENS AG (SIEMENS HEALTHINEERS), DANAHER CORPORATION (BECKMAN COULTER, INC.), ABBOTT LABORATORIES, BIO-RAD LABORATORIES, INC., BIOMÉRIEUX SA, QIAGEN N.V., SYSMEX CORPORATION |
In vitro diagnostics (IVD) include medical devices, assays and reagents, which are employed in diagnosis of a medical condition. Furthermore, these instruments are employed in analysis of tissue samples and body fluids collected from a patient. Moreover, there are various types of in vitro diagnostic instruments that work on different techniques such as immunodiagnostics, tissue diagnostics, hematology, and molecular diagnostics. Furthermore, in vitro diagnostics are employed in diagnosis of various medical conditions such as infectious diseases, cancer, cardiac disorders, and nephrological disorders. Moreover, use and handling of in vitro diagnostics require technical expertise and thus, instruments are used in specialized medical facilities to carry out diagnosis. For instance, IVD products are used in facilities such as standalone laboratories, hospitals, and point-of care.
The major factor that contributes to the growth of the Europe in vitro diagnostic market is surge in number of in vitro diagnostic tests, which is attributable to rise in incidences of chronic and infectious diseases. Furthermore, growth in geriatric population, which is prone to immunological disorders is another major factor that boosts the growth of the market. Moreover, rise in use of personalized medicines in treatment of various chronic diseases such as cancer also fuels growth of the Europe in vitro diagnostics market. In addition, increase in technological advancements associated with in vitro diagnostic products, technologies, and software & services boosts the market growth. However, stringent government regulations and unfavorable reimbursement policies are anticipated to restrict growth of the Europe in vitro diagnostics market. On the contrary, potential for outsourcing present lucrative opportunities for key players in the Europe in vitro diagnostics market during the forecast period.
Europe In Vitro Diagnostics (Ivd) Market Segmentation
The report segments the market into product & service, technique, application, end user, and region. On the basis of product & service, the market is segmented into chemicals & reagents, instruments, and services & software. On the basis of technique, it is categorized into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. In addition, the immunodiagnostics segment is further divided into enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. Moreover, the ELISA segment is further divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Similarly, the molecular diagnostics segment is divided into polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others.
The clinical chemistry segment is further divided into basic metabolic panel, liver panel, lipid profile, thyroid function panel, electrolyte panel, specialty chemicals, and others.
On the basis of application, the market is segmented into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. On the basis of end user, it is categorized into standalone laboratories, hospitals, academics & medical schools, point-of-care, and others. Country wise, the market is analyzed across Germany, France, the UK, Italy, Spain, and rest of Europe.
Some of the prominent players in the Europe In Vitro Diagnostics Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Europe In Vitro Diagnostics market.
By Product Services
By Application
By End User
By Country